tirzepatide pdf 2025 Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial | Diabetes Therapy Frontiers | Efficacy and safety

Starting with smaller amounts allows the human body to adjust gradually

SURMOUNT-1 results In this 72-week obesity trial, participants receiving tirzepatide achieved remarkable weight loss results: 5 mg dose: 85% achieved at least 5% weight reduction, with average weight loss of 15% 10 mg dose: 89% achieved at least 5% weight reduction, with average weight loss of 19% 15 mg dose: 91% achieved at least 5% weight reduction, with average weight loss of 21% These results were achieved with consistent weekly dosing

Tailored treatment plans: We integrate medication with lifestyle and wellness guidance to support long-term success

Civil Engineering, UCLA Last updated: July 2026 Human-researched and AI-assisted with full editorial review

[1] [4] Based on data from major clinical trials and FDA prescribing information, heart rate increases with semaglutide are relatively common but typically modest in magnitude

G.HeiseT.Plum-MoerschelL.et al (2018)